News
RNA-Targeted Drug Approved for Preventing Hereditary Angioedema Attacks
In June, the monoclonal antibody garadacimab (Andembry) was approved for prevention of HAE attacks at a dose of once monthly subcutaneously. Weeks later, regulators approved sebetralstat (Ekterly) as an oral, on-demand therapy for HAE.
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.
Stocktwits on MSN2h
Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy
Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera ...
Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback